November 24, 2011

Genovis AB nomination committee appointed

Regulatory
As decided by the 2011 Annual General Meeting (AGM), a nomination committee has been appointed composed of:

Mikael Lönn, holdings 22,26%

Jörgen Wettbo represents 4,44%

Torbjörn Fridh, holdings 3,11%

Hans-Göran Arlock, holdings 1,26%

The nomination committee represents 31,07% of the total number of votes in the company.

The AGM will be held on May 24, 2012 at 5:00 PM in Genovis facilities at Scheelevägen 22 in Lund, Sweden.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.

wkr0001.pdf
  • Svenska